Cargando…

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?

Pancreatic resection still represents the only curative option for patients affected by pancreatic ductal adenocarcinoma (PDAC). However, the association with modern chemotherapy regimens is a key factor in improving the inauspicious oncological outcome. The benefit of neoadjuvant treatment (NAT) fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vivarelli, Marco, Mocchegiani, Federico, Nicolini, Daniele, Vecchi, Andrea, Conte, Grazia, Dalla Bona, Enrico, Rossi, Roberta, Benedetti Cacciaguerra, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195424/ https://www.ncbi.nlm.nih.gov/pubmed/35712487 http://dx.doi.org/10.3389/fonc.2022.914203

Ejemplares similares

Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature
por: Frosio, Fabio, et al.
Publicado: (2019)

Intraductal papillary neoplasm of the bile duct: The new frontier of biliary pathology
por: Mocchegiani, Federico, et al.
Publicado: (2023)

Fast track program in liver resection: a PRISMA-compliant systematic review and meta-analysis
por: Ahmed, Emad Ali, et al.
Publicado: (2016)

ALPPS Procedure for Extended Liver Resections: A Single Centre Experience and a Systematic Review
por: Vivarelli, Marco, et al.
Publicado: (2015)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
por: Chawla, Akhil, et al.
Publicado: (2019)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer
por: Hussien, Nervana, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Pushing the Limits of Cancer Therapy: The Nutrient Game
por: Lettieri-Barbato, Daniele, et al.
Publicado: (2018)

Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol
por: Lee, Jong-chan, et al.
Publicado: (2016)

Neoadjuvant Treatment in Pancreatic Cancer
por: Oba, Atsushi, et al.
Publicado: (2020)

Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer
por: He, Chaobin, et al.
Publicado: (2021)

Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation
por: Nicolini, Daniele, et al.
Publicado: (2017)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
por: Choi, Jin Ho, et al.
Publicado: (2022)

Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications
por: Cacciato Insilla, Andrea, et al.
Publicado: (2020)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Postoperative Insulin-Like Growth Factor 1 Levels Reflect the Graft’s Function and Predict Survival after Liver Transplantation
por: Nicolini, Daniele, et al.
Publicado: (2015)

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
por: Katz, Matthew H. G., et al.
Publicado: (2010)

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2022)

Conversion Surgery for Pancreatic Cancer—The Impact of Neoadjuvant Treatment
por: Klaiber, Ulla, et al.
Publicado: (2020)

Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer
por: Yang, Liqiong, et al.
Publicado: (2021)

Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients
por: Barchiesi, Francesco, et al.
Publicado: (2016)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review
por: Han, Dan, et al.
Publicado: (2022)

Neoadjuvant therapy for resectable pancreatic cancer
por: Rahman, Sheikh Hasibur, et al.
Publicado: (2017)

Neoadjuvant therapy for resectable pancreatic cancers
por: Inoue, Yosuke, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
por: Lv, Wanrui, et al.
Publicado: (2022)

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer
por: Wittmann, David, et al.
Publicado: (2020)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05)
por: Takahashi, Shinichiro, et al.
Publicado: (2017)

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2020)

Is neoadjuvant chemoradiotherapy for pancreatic cancer beneficial: A systematic review and meta-analysis
por: Luo, Wenhao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nu2haci8h2pcrqo99t066a7urn